BIND Therapeutics

Performance

About BIND Therapeutics

BIND Therapeutics was a biotechnology company specializing in the development of targeted polymeric nanoparticle therapeutics, known as ACCURINS®, designed to deliver treatment directly to specific cells and tissues. Incorporated in 2006, the company's innovative approach aimed to improve therapeutic outcomes beyond traditional methods. In 2016, Pfizer acquired most of BIND Therapeutics' assets and continues to develop the ACCURINS® technology.